Navigation Links
Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/17/2011

ot be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the Company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide the Company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the Company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010 and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that an
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
2. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
3. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
4. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
5. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
6. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
7. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
8. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
9. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
10. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
11. Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July ... REGN ) and Sanofi (EURONEXT: SAN and NYSE: ... 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia ... reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at ... is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase ...
(Date:7/30/2014)... and NEW YORK , July 30, ... developer of new products for oncology supportive care, announced ... , has been featured in an article on OncLive.com ... in Head and Neck Cancers."  Dr. Steve Sonis ... on the growing demand seen in the oncology community ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... 12, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX), today ... efforts will be presented at the 98th,Annual ... Research,April 14-18, 2007 in Los Angeles, CA., ... Therapy", Heilbut, et.al. (Abstract #1410) will be ...
... Oncology Portfolio, SOUTH SAN FRANCISCO, Calif., April ... the presentation of four research projects aimed ... as,potential therapeutics for certain types of cancers ... presentations during,poster sessions from April 16th to ...
Cached Medicine Technology:CombinatoRx to Present Combination High Throughput Screening (cHTS),Data at Upcoming AACR Meeting 2CombinatoRx to Present Combination High Throughput Screening (cHTS),Data at Upcoming AACR Meeting 3Rigel to Present New Research Programs at AACR Meeting 2Rigel to Present New Research Programs at AACR Meeting 3Rigel to Present New Research Programs at AACR Meeting 4Rigel to Present New Research Programs at AACR Meeting 5
(Date:7/30/2014)... being revitalized and expanded through a U.S.-funded effort ... Internet access and providing cutting-edge skills labs and ... publication by participants of the $130 million Medical ... detailed progress being made at the African institutions. ... today by the journal Academic Medicine . ...
(Date:7/30/2014)... Good Neighbor Community Services announced that ... of Innovations with Ed Begley Jr, airing later ... times TBA. , In this segment, viewers will ... to redefine the traditional approach to serving the ... passion, innovation, determination, excellence, and collaboration, Good Community ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- It can happen in ... television, dresser or computer monitor and gets critically injured when ... a young child should look around their homes and imagine ... child. Imagining it is better than it becoming a reality," ... Physicians, said in a college news release. Between 2009 ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... 2014 Visitors to our region recognize ... to ensure its protection. Bob Kiesendahl, one of the ... the Delaware Highlands Conservancy for donations collected through participation ... donations add up fast, as visitors welcome the opportunity ... River Region. , The Kiesendahl family has owned Woodloch ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2
... 30 The American Lung,Association of Iowa will host a week ... 2008. The camp is open for all children with,asthma from ages ... for kids with asthma to spend a week doing,things all other ... Lung Association, "It is a chance for kids to learn that,having ...
... PORTLAND, Ore. Men with a certain type of ... new chemotherapy drug, Sagopilone, plus prednisone in an international ... Institute researchers. , The research involved men with ... has spread beyond the prostate and is not longer ...
... Dynamic Student Services ... ... ) the architectural, planning and interiors,firm, has transformed a shuttered South ... Golden Gate,University (GGU). As the new "front door" for the downtown ...
... masses in the colon is the same for average-risk patients ... who are 50 to 59 years of age, reports a ... the American Gastroenterological Association (AGA) Institute. , Currently, standard ... cancer based on the increasing incidence of colon cancer at ...
... learn CPR/AED, WASHINGTON, May 30 Sudden ... people in this country every year.,Sadly, an astonishing ... arrest,die before reaching a hospital. If ordinary people ... Automated External,Defibrillator (AED), instead of just waiting for ...
... looks hopeful, but it,s still too early to make ... 30 (HealthDay News) -- An antioxidant found in green ... a toxic protein associated with Alzheimer,s and Parkinson,s disease, ... seen in the brains of Alzheimer,s patients and appears ...
Cached Medicine News:Health News:OHSU Cancer Institute researchers find novel chemo drug helps treat prostate cancer 2Health News:Golden Gate University Opens New Student Services Center 2Health News:Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s 2Health News:Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s 3Health News:National CPR/AED Awareness Week 2Health News:Green Tea Antioxidant May Help Prevent Alzheimer's 2Health News:Green Tea Antioxidant May Help Prevent Alzheimer's 3
1.0 mm diameter head, 0.75 mm deep bite....
Target illumination for day and night testing. Glare luminance distance. The Optec 3500 remote control offers flexible positioning during test administration. Each vision tester includes 12 tests sli...
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Medicine Products: